Stock Screener App

Frei -

Installieren

18.80

4.79% 0.86

after-market

Handel nachbörslich: 18.69 -0.11 -0.59%

Sarepta Therapeutics Inc (SRPT)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SRPT? Forum Prognose Aktiensplit

Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten

2025-08-12 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside - MarketBeat

Sarepta details Elevidys’ liver toxicity data and plans for safety study - Endpoints News

Caught In Sarepta ‘Downdraft,’ Arrowhead Becomes RNAi Knight in Shining Armor - BioSpace

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - FinancialContent

Levi & Korsinsky Urges Sarepta Therapeutics, Inc. (SRPT) Shareholders to Act Before Lead Plaintiff Deadline August 25, 2025 - ACCESS Newswire

SAREPTA (SRPT) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Vinay Prasad returns to role as top vaccine regulator at FDA days after leaving US agency - Reuters

August 25, 2025 Deadline Approaching: Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)Contact Levi & Korsinsky - Newsfile

SRPT COURT REMINDER: Sarepta Therapeutics, Inc. was Sued for Fraud -- Investors are Notified to Contact BFA Law by August 25 Deadline - ACCESS Newswire

Sarepta Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire

Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire

Sarepta stock rises as Jefferies reiterates Buy rating after Elevidys shipments resume - Investing.com Canada

Sarepta stock rating upgraded to Buy by Freedom Broker on ELEVIDYS supply resumption - Investing.com Canada

A mild market reaction for companies on Prasad’s return - BioWorld MedTech

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga

SRPT LAWSUIT ALERT: The Gross Law Firm Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Barchart.com

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Unexpected Shifts in the Gene Transfer Technologies Market - openPR.com

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have - GlobeNewswire

Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com

Vor Bio lures Sarepta exec to be its CCO - The Pharma Letter

SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics - TipRanks

Biotech sector slips amid reported return of ousted FDA official - MSN

Biotech sector slips amid reported return of ousted FDA official (SRPT:NASDAQ) - Seeking Alpha

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - Defense World

Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) InvestorsLead Plaintiff Deadline on August 25, 2025 - ACCESS Newswire

Shareholders of Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights Before August 25, 2025Contact Levi & Korsinsky - ACCESS Newswire

SRPT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SRPT - GlobeNewswire Inc.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - TradingView

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 at The Goldman Sachs Group - Defense World

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $19.00 - Defense World

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

2025-08-09 | Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline | NDAQ:SRPT | Press Release - Stockhouse

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT | FinancialContent - FinancialContent

SRPT INVESTOR NOTICE: Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire

Shareholders that lost money on Sarepta Therapeutics, - GlobeNewswire

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar

SRPT ALERT: BFA Law Urges Sarepta Therapeutics, Inc. Investors with Losses to Contact the Firm before the Imminent August 25 Court Deadline - Newsfile

SRPT Deadline: SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com

Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com

Securities Lawsuit Alert: Sarepta Therapeutics, Inc. (SRPT) InvestorsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com

Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com

Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive

As gene therapies falter on the market, this biopharma is aiming to defy the odds - PharmaVoice

Vor Bio hires former Sarepta exec to lead commercial strategy; Mallinckrodt poaches CFO from Incyte - Endpoints News

How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com

Sarepta soars as revenue beats estimates on Elevidys milestone - The Boston Globe

Sarepta Shares Surge 10.46% on Record Q2 Revenue Despite Safety Scrutiny Trading Volume Ranks 407th - AInvest

Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Class Action Filed Against Sarepta Therapeutics, Inc. - GlobeNewswire

Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)August 25, 2025 Deadline to Join – Contact The Gross Law Firm - Morningstar

Sarepta’s Stock Surges as FDA Lifts Elevidys Hold - StocksToTrade

Sarepta Gets A Price Target Hike From Wells Fargo: Retail Highlights Consistent Demand For Elevidys - Stocktwits

Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky to Join Class Action Before August 25, 2025 - ACCESS Newswire

Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings - statnews.com

Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries - Yahoo Finance

Cautious Outlook on Sarepta Therapeutics Amid Financial Strain and ELEVIDYS Challenges - TipRanks

Despite Safety Drama, Sarepta Beats Q2 Estimates—But No Thanks to Elevidys Sales - BioSpace

Sarepta Therapeutics stock price target raised to $50 by Wells Fargo - Investing.com

Sarepta Soars as Revenue Beats Estimates on Elevidys Milestone - Bloomberg.com

Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insig - GuruFocus

Sarepta Therapeutics Reports Strong Revenue Growth Amid Strategic Investments - TipRanks

SRPT SHAREHOLDER NEWS: The Sarepta Therapeutics, Inc. Securities Fraud Class Action is Pending -- Investors with Losses are Urged to Contact BFA Law before August 25 - ACCESS Newswire

RPRX

$35.86

0.91%

INCY

$81.61

3.06%

SMMT

$25.68

9.08%

INSM

$122.00

8.07%

BNTX

$111.00

1.59%

ONC

$288.10

0.57%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters